Overcoming Skepticism About Cancer Diagnostics
This article was originally published in Start Up
Executive Summary
In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.
You may also be interested in...
Please Do Squeeze the Tumor Cell
A team at UCLA used nanomechanics to show that tumor cells are significantly more elastic than normal cells, suggesting that stiffness can accurately distinguish them from normal cells. The technique could be readily adopted in pathology labs to improve the accuracy of traditional cytology analysis using standard sample preparation and processing. Moreover, there may be an immediate opportunity to use it to diagnose mesothelioma, which is not now possible using visual analysis.
J&J's Franchise in Cancer Diagnostics
J&J isn't the ground-shaker in molecular testing that Roche Diagnostics is--so it is forging a different path to becoming a leader in emerging high-potential sectors of the in vitro diagnostics industry. It formed a subsidiary Veridex, dedicated to cancer diagnostics. That subsidiary is assembling a platform of core technologies and recently completed several deals, including in-licensing prostate cancer markers based on methylation, a hot area of research, from start-up Oncomethylome Sciences.
J&J's Franchise in Cancer Diagnostics
J&J isn't the ground-shaker in molecular testing that Roche Diagnostics is--so it is forging a different path to becoming a leader in emerging high-potential sectors of the in vitro diagnostics industry. It formed a subsidiary Veridex, dedicated to cancer diagnostics. That subsidiary is assembling a platform of core technologies and recently completed several deals, including in-licensing prostate cancer markers based on methylation, a hot area of research, from start-up Oncomethylome Sciences.